Clinical Trial Update: An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease [Phase 3]

View source ↗

Summary

An open-label extension study evaluated the safety and tolerability of long-term rotigotine treatment in patients with idiopathic Parkinson's disease (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease

Drugs mentioned

• Rotigotine (rotigotine)

Snippet

Sponsor: UCB Pharma | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2010-01-12